Interferon
Sponsors
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Cancer Institute (NCI), Bayer, PETHEMA Foundation, M.D. Anderson Cancer Center
Conditions
Acute Myeloid LeukemiaBlast CrisisBrain MetastasesCOVID-19 InfectionCarcinoma, Renal CellChronic Hepatitis BChronic Hepatitis B InfectionChronic Hepatitis C
Phase 1
IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma
WithdrawnNCT01409187
Start: 2011-10-31Updated: 2012-01-26
Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease
CompletedNCT01605513
Start: 2011-06-30End: 2013-12-31Updated: 2016-01-26
Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases
Not yet recruitingNCT07199413
Start: 2026-03-01End: 2029-04-01Target: 20Updated: 2025-09-30
Phase 2
Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer
CompletedNCT00001228
Start: 1988-10-25End: 2007-09-06Target: 50Updated: 2017-07-02
Treatment and Natural History Study of Lymphomatoid Granulomatosis
CompletedNCT00001379
Start: 1995-05-05End: 2025-01-17Updated: 2025-06-19
BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma
CompletedNCT00117637
Start: 2005-06-30End: 2009-03-31Updated: 2014-10-31
Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive
CompletedNCT00763763
Start: 2004-12-31End: 2010-01-31Updated: 2011-10-05
A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma
NCT01782508
Start: 2012-08-31End: 2014-12-31Target: 40Updated: 2013-02-04
Assessing the Effectiveness and Safety of Interferon Bladder Infusion for the Treatment of Interstitial Cystitis
NCT05912946
Start: 2023-10-15End: 2024-10-15Target: 129Updated: 2023-09-15
Phase 3
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
CompletedNCT00577993
Start: 1998-03-16End: 2017-08-24Updated: 2020-11-16
Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia
RecruitingNCT06802718
Start: 2023-01-01End: 2026-12-31Target: 96Updated: 2025-01-31
Phase 4
Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia
CompletedNCT00390897
Start: 2003-07-31End: 2007-12-31Target: 360Updated: 2008-11-27
Antiviral Therapy in Infants With HBV Infection
Not yet recruitingNCT06503796
Start: 2024-08-31End: 2026-11-30Target: 60Updated: 2024-07-23
Unknown Phase
The Curative Effect and Security of Interferon Combined Resveratrol on HBeAg Positive Chronic Hepatitis B Patients
CompletedNCT03546530
Start: 2016-06-01End: 2017-01-31Updated: 2020-10-14
Cohort Study of Clinical Outcomes in Chronic HBV Infection Patients With Low HBsAg Under Unplanned Intervention
NCT04030039
Start: 2017-05-01End: 2020-12-30Target: 420Updated: 2019-07-23
Cohort Study of Efficacy and Safety of Interferon Intermittent Treatment of Chronic Hepatitis B
CompletedNCT04028856
Start: 2018-06-01End: 2019-06-30Updated: 2019-07-23
Observational Cohort Study of Clinical Outcomes After Antiviral Therapy for Chronic Hepatitis C
NCT04071353
Start: 2019-08-01End: 2020-08-01Target: 1000Updated: 2019-08-28
A Cohort Study on Long-term Clinical Outcomes of Antiviral Therapy in Patients With Chronic Hepatitis B and Cirrhosis
NCT04301908
Start: 2020-04-01End: 2021-04-01Target: 10000Updated: 2020-03-10
Study of COVID-19 Infection and Its Clinical Prognosis in Chronic Hepatitis B Patients With Antiviral Therapy
NCT05792878
Start: 2022-09-01End: 2023-12-01Target: 600Updated: 2023-03-31